My Lung Cancer Journey To Date

Since most people reading this will not know my lung cancer history, I thought I’d put it in a post to help you see the ups and downs of living with lung cancer. Here’s the Readers Digest version, sans the roller coaster of scanxiety every 2-3 months.

In early 2011, I was in good physical shape, about 30 pounds overweight, eating healthy and exercising regularly. After tolerating a nagging, slight cough for a few months, I visited my primary care doctor at Virginia Mason Seattle in early March 2011 and went home with a Z-pak of antibiotics. A few weeks later, I along with my husband and son returned from a trip abroad with respiratory infections. The guys recovered in a couple of weeks. I kept coughing up thick green gunk. When I coughed up blood, I went back to the doctor, who gave me another Z-pak. After another few weeks, I was still coughing heavily, so the doctor ordered a chest x-ray. Before I’d left the lab, she ordered a CT scan. By the time I arrived home from the clinic (a 10-minute drive), she called me. The radiologist saw a mass in my lung that looked like a carcinoma. Two days later, a Friday, I saw a pulmonologist (lung specialist) who performed a diagnostic bronchoscopy. I had a very anxious weekend waiting for the pathology results. The pulmonologist called me Tuesday evening, May 10, 2011, with the news. I was 56 and I had lung cancer.

I’d never smoked anything except a salmon, never lived with smokers except in a college dorm, never worked in a heavy smoking environment (although I did grow up downwind of the ASARCO copper smelter in Tacoma, which belched arsenic and lead into the air for years).

Subsequent scans and tests over a two-week period rendered a diagnosis of stage IIIA non-small-cell adenocarcinoma. I had a 7-inch tumor in my lower left lung, two hot hilar lymph nodes in the left lung, and one hot subcarinal lymph node between my lungs at the bottom of my windpipe. All biopsies showed poorly differentiated cells, which indicates an aggressive cancer. At diagnosis I had severe pneumonia; turns out the interior of my tumor had died off and become colonized by bacteria that took the University of Washington three weeks to identify. Heaven forbid I should be a boring, vanilla cancer patient!

At this point my white blood cell count was in the mid 20s (normal is 6-10). I was unable to have surgery due to the pneumonia and lots of inflammation between my lungs (even an extra artery there, presumably feeding the cancer). I would have required a pneumonectomy (complete removal of my left lung), and the surgeon thought I wouldn’t heal properly.

However, the oncologist said he considered me curable. After 10 days in the hospital and weeks of IV antibiotics, I recovered enough from pneumonia to get 33 daily radiation treatments (66 Grays total) concurrent with 6 weekly chemo doses (both carboplatin and paclitaxel) followed by one full chemo dose. I couldn’t have the second planned full chemo dose because my blood values tanked in addition to other side effects. Treatment finished in early August 2011, though I stayed on oral antibiotics to keep the pneumonia at bay.

Update Oct 2011:
My first post-treatment CAT scan in late September 2011 showed the lymph nodes were almost completely resolved, and the tumor had shrunk by over 90%! I was feeling good, the CAT scan was good … I thought I had a great chance at a cure.

In the next two weeks, I underwent several tests (15 appointments in 16 days) to determine if I was healthy enough to have the lung removed. Lung surgery isn’t often done after curative chemo and radiation treatment, because the radiation scars the lungs and complicates the operation and healing. One of the tests was a PET scan, which found a hot spot on my right front collarbone. A few days later two lymph nodes were removed in an open biopsy and found to be more of the same cancer. So now I’m stage IV (borderline IIIB). No lung surgery for me–no point undergoing a risky surgery with a tough recovery when it wouldn’t cure me.

Late October 2011:
Developed shortness of breath. Pulmonologist diagnosed me with radiation pneumonitis and put me on oral prednisone, a steroid. I’d be on it for most of the next year.

Update Dec 2011:
A new tumor grew by my right collarbone in the area where the nodes were removed. It’s an ugly thing that grew from nothing to about 3 inches long and 1.5 inches wide in less than 2 months–very aggressive. My pulmonologist and oncologist say they’ve never seen anything grow so fast. The Lung Cancer Mutation Consortium Protocol clinical trial says I have none of the 10 mutations on their panel, which means I’m unlikely to benefit from or are not eligible for any targeted therapies.
We’re going to shrink it with Alimta-Avastin chemo, then decide on next steps. I had a port installed (on the left side, in case we decide to radiate the tumor later).

Update January 2012:
The Alimta-Avastin started shrinking the tumor by the 10th day of my first round. One good thing about fast-growing tumors is that they suck up chemo fast, too. However, I lost my voice and the shortness of breath came back. Increased the prednisone. I understand Roid Rage better now.

Update June 2012:
Now, after 6 rounds of chemo over 5 months, CT and brain MRI scans say all my original tumors are gone, the aggressive tumor on my right collarbone shrank over 90% to 1.7×1.5 cm, and no new tumors have appeared. I’m glad to be off the chemo; towards the end, I felt like I continually had the flu. My team figures if any new mets of this aggressive cancer were going to appear, they would have shown up by now. We’ve decided to treat this one remaining tumor as an oligo-recurrence and go for a possible cure. I’ve started radiation therapy that will last 6-7 weeks and hopefully knock this cancer out for good!

Update Sep 16, 2012:
Completed radiation over the tumor bed on July 31 (28 treatments totalling about 57 Grays). The skin on my neck and by my collarbone was raw by the end, but healed quickly. Five weeks later, the skin on the back of my shoulder just looks lightly tanned, and the skin in front is pink and a tad tender. I can still feel a lump where the tumor was, but it’s just scar tissue — my Sep 13 PET/CT scan shows no activity near my collarbone. However, I have a new nodule suspicious for cancer in my upper right lobe (2×2 cm, SUV of 7), and a 7mm nodule in my lower right lobe (too small to biopsy). So, more procedures: CT scan, brain MRI, and a third bronchoscopy for an URL biopsy. This bronchoscopy will be done with electromagnetic navigation similar to GPS technology because it can’t be accessed by other methods. I’m also planning to restart chemo with Alimta only. As my onc says, “Your cancer has never progressed while you’re on chemo.” At least I was able to finally stop the oral Augmentin after 16 months.

Update Sep 17, 2012:
While visiting family in Denver, I was able to meet with Dr. Bunn of the LCMC (which ran molecular testing for 10 mutations on my recurrent tumor last fall). He told me the University of Colorado at Denver now tested for 4 new mutations, including ROS. They will test my remaining slides for ROS and RET–Dr. Bunn says I have a 10-20% chance of having one of those mutations.

Update Sep 24, 2012:
Had my electromagnetic navigation bronchoscopy today. My pulmonologist said he got a good sampling of the new nodule but couldn’t find any cancer cells. Could I be NED?

Update Sep 25, 2012:
Dr. Bunn emailed me: I have “an impressive ROS1 rearrangement”! They have an opening in a Xalkori trial for me, if I want it. Xalkori is twice-daily pill that targets only cells that have the ROS1 mutation, so it has substantially fewer side effects than chemo.

Update Sep 26, 2012:
AM: Oncologist called, excited by ROS1 news. He’s still suspicious the new nodule is cancer; if it is, he agrees I should enter the ROS1 trial rather that restart Alimta. Dr. Bunn says I can join the trial later if I don’t have active cancer now.
PM: Pulmonologist called–he took my case to the Tumor Board today (surprise!). Lots of discussion but consensus says the biopsied nodule is radiation changes. I restart 15 mg prednisone tomorrow. This is GOOD news, but not the convincing declaration of NED I’d prefer. In a month I have a CT which will hopefully determine if the URL nodule is shrinking (probably pneumonitis) or growing (BOOP or cancer?), and whether LRL nodule is growing (might need another biopsy).

Update Oct 24, 2012
Chest CT shows LRL nodule grew nearly 50% from 9×7 mm to 13×10 mm. I need to restart treatment–either a trial, or Alimta. I’ll call the University of Colorado Cancer Center (UCCC) in Denver tomorrow to enroll in their ROS1 crizotinib trial. Bright spot: Prednisone did not affect URL inflammation, so I get to ramp down over 3 weeks (yay).

Update November 6, 2012:
Last week I flew to Denver to get screened for the ROS1 clinical trial. Today I learned I have been accepted into the trial! Tomorrow, bright and early, I will be at UCCC to get my first dose of Xalkori (also known as crizotinib).

Update January 2, 2013:
The UCCC PET/CT scan, done 8 weeks after starting Xalkori, showed one of my two lung nodules is gone, the other is shrinking, and no new hot spots have popped up. Xalkori is working! The side effects (edema and constipation) are far easier than chemo. Hoping this drug will keep working for a LONG time.

Update January 11, 2013:
My oncologist at Virginia Mason in Seattle had my PET/CT read by their radiologist. The VM verdict is No Evidence of Disease. Woohoo! This is my first clean scan since my diagnosis.

Update February 26, 2013:
Yesterday’s PET/CT scan again showed No Evidence of Disease. Still battling significant edema and now joint pain, especially in my hands, but my energy is increasing. I’ve added regular acupuncture and lymphatic drainage massage to my therapies.

New blood test for early detection of lung cancer?

Today I attended a Caltech alumni event and had the great pleasure of meeting Dr. Leroy Hood, MD, PhD, who was recently awarded the National Medal of Science . He invented the first DNA sequencing technology and founded the fields of genomics (sequencing, assembling, and analyzing the function and structure of genomes) and proteomics (the study of large-scale proteins, particularly their structures and functions).

This brilliant doctor and decorated scientist has cofounded a startup company that is planning to market a blood test for early detection of lung cancer later this year. The science has yet to be published (due to understandable intellectual property concerns), but based on Hood’s prior accomplishments, I’m very hopeful this venture has a genuinely useful product to offer. Here are a couple of articles I found indicating this venture is real:

InDi, Lee Hood’s Vision for Spotting Cancer in Blood, Snags $10M

Integrated Diagnostics(R) Appoints CFO & VP Sales Prior to Launch of Lung Cancer Diagnostic

Diabetes Slows the Progress of Alzheimer’s

People with diabetes are known to be at higher risk for developing Alzheimer’s disease.  However, the interaction between the two diseases is not well understood.  A French study published 10/27/2009 just found that Alzheimer’s progresses more slowly in people who have diabetes.   An article on DiabetesHealth.com says:

“Diabetes is thought to increase the risk of developing Alzheimer’s, possibly because of vascular damage in the brain that mimics the dementia seen with Alzheimer’s.  But once patients display symptoms of the disease, the current study suggests that the progression is slower than in people without diabetes. … One complication may be that the medications used to help control blood sugar have a protective effect on the brain….”

http://www.diabeteshealth.com/read/2009/10/29/6427/diabetes-and-alzheimers-disease/

Jumping with Glial

Most of us have heard of neurons.  But have you ever heard of glial cells?   They make up almost 90% of the brain, and science is beginning to explore what they do and how they might contribute to thought.  Originally thought to simply be the “brick and mortar” that insulated neurons,  glial cells are now known to communicate with each other and with neurons,.  They can produce neurotransmitters, and they appear to be essential for forming new neurons and connections between neurons.  Who knew?

Scientific American interviewed Andrew Koob (Ph.D. is neuroscience from Purdue University) about glial cells and why they orginally got no respect.

http://www.scientificamerican.com/article.cfm?id=the-root-of-thought-what&print=true

Concussions can lead to dementia

The “60 Minutes” TV program recently ran a segment on long-term effects of concussions sustained in sports.  First associated with pro boxers, chronic traumatic encephalopathy (CTE) is a condition seen only in people who suffer repeated dazing blows to the head.  It is  diagnosed after death by examining brain tissue for abnormal proteins that show up as dark brown pigment in brain sections.  These proteins are neurofibrillary tangles of tau, which are also characteristic of Alzheimer’s and other dementing illnesses.  CTE has been diagnosed in the brains of several deceased pro football players over the past few years.

Dr. Ann McKee, a neuropathologist at Boston University School of Medicine, has been working on a brand new area of research on the brain that has provided physiological proof of brain disease in athletes who have suffered concussions.  …

“I’ve looked at brains from people that have lived to be 110. And you just don’t see anything like this, what we see in these athletes,” she told Simon

Even more troubling, she says, CTE actually progresses undetected for years, silently eating away at brain cells, until it causes dementia and other cognitive problems.

“It seems to be triggered by trauma that occurs in a person’s youth; their teens, their 20s, even their 30s. But it doesn’t show up for decades later,” she explained. “People think it’s a psychological disease or maybe an adjustment reaction, maybe a mid-life sort of crisis type of thing. But actually, they have structural disease. They have brain disease.”

Dr. McKee’s research found that athletes in any contact sport are at risk of permanent brain damage.

You can see the video and read more at  http://www.cbsnews.com/stories/2009/10/08/60minutes/main5371686.shtml

In retrospect, I sure am glad dear old Dad (a general practioner) forbade me from playing contact sports while growing up!

Why Is the “Placebo Effect” Getting Stronger?

The brain has an amazing capacity to help the body heal itself.  The “placebo effect” was first described in a 1955 medical paper:  people given a harmless sugar pill – a “placebo” – will feel less pain if they are first convinced the pill is a medicine that effectively relieves pain.  Placebos are effective for a variety of symptoms like depression and stomach ulcers, too.

Since 1962, the US Food and Drug Administration (FDA) has required drug makers to prove a new medicine is more effective than a placebo before it will approve the drug for market.  For some reason, placebos seem to be more effective than expected in drug trials between 2001-2006, especially for meds targeting the brain and central nervous system.  As a result, more new drugs fail to pass FDA approval because they don’t produce results better than sugar pills.  Even old standbys like Prozac are proving less effective against placebos than when they were first tested in the 80s.

The increase in placebo effectiveness is significant enough that the NIH is studying the phenomena, funded by big pharmaceutical companies.  Wired Magazine has a great article on the increase in placebo effectiveness here.

One study mentioned in the article talks about the placebo effect in Alzheimer’s disease (AD) patients.  To be effective, placebos require the patient to have cognitive ability – you have to understand what the pill will do for you before your brain will activate your body’s natural response.  A person with AD may have suffered enough brain damage that they’re unable to grasp that concept.  As a result, AD patients generally require more painkiller than the average person because the AD patients don’t get the benefit of the placebo “boost” in effectiveness.

I anxiously await the study’s results.  It would be wonderful to learn how to make the placebo effect more powerful and let our brains do more to heal us.

Detecting Alzheimer’s Before Symptoms Appear: ADNI

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (http://www.adni-info.org/) aims “to study the rate of change of cognition, function, brain structure and function, and biomarkers” over 5 years, starting in October 2004.  Its 800+ participants–which include healthy elderly controls, subjects with mild cognitive impairment (MCI), and those with Alzheimer’s disease (AD)–undergo magnetic resonance imaging (MRI) and positron emission tomography(PET) scans along with laboratory (blood, urine, and cerebrospinal fluid, or CSF) and cognitive tests.   One unique aspect of this huge study is that data from the 58 research sites is posted online and made available free to qualified researchers.  This is the largest public-private brain research project ever funded by the National Institutes of Health.  It has spawned similar efforts in Europe, Australia, Japan, and elsewhere.

ADNI searches for biomarkers that can determine AD risk.  Blood pressure is a biomarker that helps determine risk for heart disease or stroke.  Among other things, ADNI seeks to find a combination of biomarkers that are a clear indicator of AD.

The initial ADNI goal was to create a standard assessment tool for use in AD clinical trials.   Current methods for assessing the progress of AD in patients are slow and not always reproducible.  Clear, precise measures of the disease process would make it easier to determine whether someone is improving or declining on a new treatment.  Also, if all trials were using the same measures of success, it would be easier to compare results of different treatments.  This would make clinical trials less costly and produce reliable results more quickly.

The study is flexible enough to incorporate new technologies.  After the study began, the ability to detect amyloid beta in the brain in living subjects using PET was demonstrated.   This was the first time the characteristic accumulation of the protein in the brain could be confirmed without benefit of autopsy. This measurement was added to the study at some sites.

As ADNI research progressed and scientists became aware of new ways its data could be applied, the study’s goals expanded.  Over 800 blood samples underwent whole genome analysis as part of the search for AD-associated genes.  The ADNI samples have the benefit of donor brain scans and lab data available to researchers.  Analysis has identified several new genes (in addition to the 4 known early onset AD and 1 late onset AD genes) as targets of study, and researchers are working to confirm they are associated with increased risk of AD.  http://homepages.indiana.edu/web/page/normal/10543.html

Near the end of the study, ADNI is yielding fascinating results.  Detecting the beginnings of AD, before the onset of symptoms, might allow treatments that postpone onset of symptoms and maybe someday even prevent symptoms from occurring.  It’s long been known that amyloid beta and tau proteins accumulate in the brains of AD victims.  Tools like MRIs and CSF tests may reliably detect AD before symptoms appear and predict whether MCI will convert to AD.   One ADNI result shows when people develop AD, the concentration of amyloid beta 42 in CSF drops and tau increases.  http://www.medicinenet.com/script/main/art.asp?articlekey=92513

ADNI ends in October 2009, with final results reported in 2010.  To date over 25 papers have been published with many more under review and presented at conferences.  Proposals are in work for ADNI 2.

Article on Alzheimer’s disease research

My article “Preserving the Memory” appears in the July/August 2009 issue of Analog Science Fiction and Fact.   Thanks to Dr. Thomas D. Bird, Professor of Medicine and Neurology at the University of Washington and Chief of their Division of Neurogenetics, for reviewing the article for accuracy.  He said he thought it was “a good review of the state of the art” in Alzheimer’s disease (January 2009).